Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/16/2863573/0/en/Compass-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-1-Study-of-CTX-8371-in-Patients-with-Solid-Tumors.html
https://www.globenewswire.com/news-release/2024/04/12/2862132/0/en/Compass-Therapeutics-Announces-Poster-Presentations-at-the-Cholangiocarcinoma-Foundation-2024-Annual-Conference.html
https://www.globenewswire.com/news-release/2024/04/10/2860690/0/en/Compass-Therapeutics-to-Participate-in-the-Stifel-Targeted-Oncology-Days.html
https://www.globenewswire.com/news-release/2024/04/09/2860242/0/en/Compass-Therapeutics-Presents-Data-Demonstrating-Elimination-of-MHC-Class-I-Negative-Tumors-in-In-Vivo-Models-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeti.html
https://www.globenewswire.com/news-release/2024/03/21/2850270/0/en/Compass-Therapeutics-Reports-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/02/29/2837924/0/en/Compass-Therapeutics-to-Participate-in-the-Leerink-Partners-Global-Biopharma-Conference.html
https://www.globenewswire.com//news-release/2024/02/28/2836911/0/en/Compass-Therapeutics-Announces-Publication-of-CTX-8371-Preclinical-Data-in-OncoImmunology-its-Bispecific-Antibody-Checkpoint-Inhibitor-now-Advancing-to-First-in-Human-Clinical-Tria.html
https://www.globenewswire.com//news-release/2024/01/05/2804605/0/en/Compass-Therapeutics-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2023/11/09/2777240/0/en/Compass-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html